Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma
Sarcomas are a diverse group of tumors with numerous oncogenic drivers, and display varied clinical behaviors and prognoses. This complexity makes diagnosis and the development of new and effective treatments challenging. An incomplete understanding of both cell of origin and the biological drivers...
Main Authors: | Rachel D. Dreher, Emily R. Theisen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1076581/full |
Similar Items
-
Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein
by: Emily R. Theisen, et al.
Published: (2021-04-01) -
Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia
by: Daniela Magliulo, et al.
Published: (2018-07-01) -
Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer
by: Barbara Majello, et al.
Published: (2019-03-01) -
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases
by: Hideaki Niwa, et al.
Published: (2017-05-01) -
Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A
by: Chao Yang, et al.
Published: (2022-07-01)